Clinical trials: Movement, Abnormal
Spinocerebellar Ataxias, Spinocerebellar Ataxia Genotype Type 1
Trial in Adult Participants With Spinocerebellar Ataxia (SCA)
The primary purpose of this study was to compare the efficacy of BHV-4157 (Troriluzole) 140 milligrams (mg) once daily versus placebo after 8 weeks of treatment in participants with spinocerebellar ataxia (SCA).
- Conditions
- Spinocerebellar Ataxias, Spinocerebellar Ataxia Genotype Type 1, Spinocerebellar Ataxia Genotype Type 2, Spinocerebellar Ataxia Genotype Type 3
- Trial name
- NCT02960893
- Testing
- Troriluzole
- Where
- 18 sites in United States
- Volunteers
- 141 people
- Sponsor
- Biohaven Pharmaceuticals, Inc.
Pain
Evaluation of the Tolerability of Switching Subjects on Chronic ATC Opioid Therapy to Buprenorphine HCl Buccal Film
The primary aim of this study is to determine if chronic pain subjects on around-the-clock opioids who are receiving 100 to 220 mg oral morphine sulfate equivalent (MSE) can be safely transitioned on to buprenorphine…
- Trial name
- NCT01871285
- Testing
- Buprenorphine, Oxycodone, Morphine sulfate
- Where
- 3 sites in United States
- Volunteers
- 39 people
- Sponsor
- BioDelivery Sciences International
Spasmodic Dysphonia, Voice Tremor
Voice Tremor in Spasmodic Dysphonia: Central Mechanisms and Treatment Response
The proposed research aims to determine brain abnormalities in patients with spasmodic dysphonia (SD) and voice tremor (VT) as the basis for characterization of central mechanisms underlying symptom improvement following the use…
- Trial name
- NCT01961297
- Testing
- Sodium oxybate
- Where
- United States
- Volunteers
- 53 people, healthy volunteers welcome
- Sponsor
- Kristina Simonyan
Chorea, Huntington
Efficacy, Safety, and Tolerability of Valbenazine for the Treatment of Chorea Associated With Huntington Disease
This is a Phase 3, randomized, double-blind, placebo-controlled study to evaluate the efficacy, safety, and tolerability of valbenazine to treat chorea in participants with Huntington disease.
- Trial name
- KINECT-HD (NCT04102579)
- Testing
- Valbenazine
- Where
- 46 sites in United States, Canada
- Volunteers
- 128 people
- Sponsor
- Neurocrine Biosciences
Parkinson's Disease, Levodopa Induced Dyskinesias (LID)
Efficacy and Safety of Amantadine Hydrochloride (HCl) ER Tablets to Treat Parkinson's Disease Patients With LID.
This study was terminated early due to slow enrollment with 87 of 162 planned subjects enrolled. The purpose of this multi-center, randomized, double-blind, parallel-group, 16 week study is to compare the efficacy and safety of…
- Trial name
- ALLAY-LID-I (NCT02153645)
- Testing
- 240mg Amantadine HCl ER tablets, 320mg Amantadine HCl ER tablets
- Where
- 56 sites in United States, Canada and 3 more
- Volunteers
- 87 people
- Sponsor
- Adamas Pharmaceuticals, Inc.
Agitation in Patients With Dementia of the Alzheimer's Type
Efficacy, Safety and Tolerability of AVP-786 for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type
Participants with agitation secondary to dementia of the Alzheimer's type. The diagnosis of probable Alzheimer's disease (AD) was to be based on the "2011 Diagnostic Guidelines for Alzheimer's Disease" issued by the National…
- Trial name
- NCT02442765
- Testing
- AVP-786
- Where
- 126 sites in United States, Estonia and 4 more
- Volunteers
- 387 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Neuroblastoma, Opsoclonus-myoclonus
Use of Rituximab in Opsoclonus-Myoclonus in Children With Neuroblastoma
The purpose of this study is to evaluate the feasibility of giving four weekly doses of Rituximab (anti-CD20 antibody) in the treatment of children with refractory neuroblastoma associated opsoclonus-myoclonus.
- Trial name
- NCT00202930
- Testing
- anti-CD20 (Rituximab)
- Volunteers
- 4 people
- Sponsor
- Jean M. Tersak, M.D.
Spinocerebellar Ataxias, Spinocerebellar Ataxia Type 1
Troriluzole in Adult Participants With Spinocerebellar Ataxia
The purpose of this study is to compare the efficacy of Troriluzole (200 mg once daily) versus placebo after 48 weeks of treatment in subjects with spinocerebellar ataxia (SCA).
- Conditions
- Spinocerebellar Ataxias, Spinocerebellar Ataxia Type 1, Spinocerebellar Ataxia Type 2, Spinocerebellar Ataxia Type 3
- Trial name
- NCT03701399
- Testing
- troriluzole
- Where
- 23 sites in United States, China
- Volunteers
- 299 people
- Sponsor
- Biohaven Pharmaceuticals, Inc.
Alzheimer's Disease, Psychosis
Treatment of Psychosis and Agitation in Alzheimer's Disease
Clinically, many patients with AD show no response or minimal response to antipsychotics for symptoms of agitation/aggression or psychosis, or they have intolerable side effects on these medications.
- Conditions
- Alzheimer's Disease, Psychosis, Agitation
- Trial name
- NCT02129348
- Testing
- Lithium
- Where
- 4 sites in United States
- Volunteers
- 77 people
- Sponsor
- New York State Psychiatric Institute
Sleep Disorders, Circadian Rhythm, Insomnia
Actigraphic Analysis of Treatment Response
The study examines and illustrates the utility of utilizing actigraphic measurements to assess treatment response.
- Conditions
- Sleep Disorders, Circadian Rhythm, Insomnia, Psychomotor Agitation
- Trial name
- NCT00723580
- Testing
- risperidone
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Child Psychopharmacology Institute
Parkinson's Disease
BradyXplore Phase II: Bradykinesia Feature Extraction System
Study objectives are to improve motion sensor algorithms for measuring bradykinesia in the clinic and the home, evaluate test-retest reliability of motion sensor algorithms for measuring bradykinesia compared to clinician raters…
- Trial name
- NCT02358876
- Where
- 2 sites in United States
- Volunteers
- 32 people
- Sponsor
- Great Lakes NeuroTechnologies Inc.
Huntington Disease
Within Subject Crossover Study of Cognitive Effects of Neflamapimod in Early-Stage Huntington Disease
This is a double-blind, placebo-controlled 2-period 10-week treatment within-subject crossover study of neflamapimod in early-stage Huntington disease (HD).
- Trial name
- NCT03980938
- Testing
- neflamapimod
- Where
- United Kingdom
- Volunteers
- 15 people
- Sponsor
- EIP Pharma Inc
Psychomotor Agitation
Comparison of Effects of Intravenous Midazolam and Ketamine on Emergence Agitation
Compare the effects of intravenous midazolam and ketamine on emergence agitation after sevoflurane anesthesia
- Trial name
- NCT02256358
- Testing
- Midazolam, Ketamine
- Volunteers
- 68 people
- Sponsor
- Inje University
Parkinson Disease
Efficacy and Tolerability of IRL790 in Parkinson's Disease Dyskinesia
Mesdopetam (IRL790) is an experimental small molecule compound with psychomotor stabilizing properties. The primary target is the dopamine D3 receptor, a target implicated in the generation of levodopa-induced dyskinesia, a…
- Trial name
- NCT03368170
- Testing
- Mesdopetam (IRL790)
- Where
- 20 sites in Sweden, United Kingdom
- Volunteers
- 75 people
- Sponsor
- Integrative Research Laboratories AB
Huntington Chorea
Efficacy and Safety on SOM3355 in Huntington's Disease Chorea
Phase IIb, randomized, double-blind, placebo-controlled study in parallel groups assessing the efficacy and safety of two doses of SOM3355 in patients suffering from Huntington's Disease with choreic movements.
- Trial name
- NCT05475483
- Testing
- SOM3355 200 mg capsules, SOM3355 300 mg capsules
- Where
- 23 sites in France, Germany and 5 more
- Volunteers
- 139 people
- Sponsor
- SOM Innovation Biotech SA
Focal Dystonia
Quantifying Musical Performance After Treatment With Myobloc in Musician's Dystonia
This study uses a computerized method of musical instrument digital interface (MIDI) quantification of performance before and after treatment with botulinum toxin type B (Myobloc ®, Solstice Neurosciences).
- Trial name
- NCT00208091
- Testing
- Botulinum toxin, type B
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- Columbia University
Huntington's Disease
Impact of Xenazine(Tetrabenazine)on Gait and Functional Activity in Individuals With Huntington's Disease
In individuals with Huntington's disease (HD), chorea may contribute to balance problems and difficulties with walking, sit to stand transfers and stair climbing that in turn may contribute to high fall rates.
- Trial name
- NCT01451463
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- Ohio State University
Tremor
Electrophysiological Study of the Effects of Limb Cooling on Essential Tremor
To determine the effects of upper limb forearm cooling on Essential Tremor upper limb tremor using a more practical method of limb cooling through a forearm cold pack.
- Trial name
- NCT01093027
- Testing
- 15 - 30, 30 - 15
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Mayo Clinic
Sphincter of Oddi Dysfunction
Evaluating Predictors & Interventions in Sphincter of Oddi Dysfunction
The Evaluating Predictors \& Interventions in Sphincter of Oddi Dysfunction(SOD) study (EPISOD) is a randomized sham-controlled study of biliary and pancreatic sphincterotomy as treatment for patients with pain after…
- Trial name
- EPISOD (NCT00688662)
- Testing
- ERCP with sphincterotomy, ERCP without sphincterotomy
- Where
- 7 sites in United States
- Volunteers
- 214 people
- Sponsor
- Medical University of South Carolina
Essential Tremor, Parkinson Disease
Physiology, Imaging and Modeling of Essential Tremor
This project aims to investigate novel ways to deliver brain stimulation to Essential Tremor (ET) patients by introducing software changes to their existing devices.
- Conditions
- Essential Tremor, Parkinson Disease, Dystonia
- Trial name
- NCT03811405
- Testing
- Active biphasic pulse stimulation---Home Settings, Active biphasic pulse stimulation---VIN Biphasic, Active biphasic pulse stimulation---Stimulator Off
- Where
- 2 sites in United States
- Volunteers
- 12 people
- Sponsor
- University of Florida